@Coherus_Bio profile picture
Coherus Oncology @Coherus_Bio

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of immunotherapies to treat cancer.

Joined February 2017
  • Tweets 695
  • Following 178
  • Followers 3,768
294 Photos and videos
P y reported Q3 2025 financial results today. Join us for a conference call and webcast where the $CHRS executive team will discuss Q3 2025 financial results and recent business highlights starting at 5 pm ET. Webcast: bit.ly/47jYekQ
4
1,255
Coherus Oncology will report Q3 2025 financial results on November 6, 2025. Starting at 5 pm EDT, the $CHRS executive team will host a conference call and webcast to discuss Q3 2025 financial results and recent business highlights. Webcast: bit.ly/47jYekQ
5
798
Coherus Oncology is attending the following Investor Conferences in November and December. For webcast links of our presentations, please visit: bit.ly/4nhV8EB To schedule 1:1 meetings during the conference, please reach out to your respective bank representative.
2
376
Attending Opal Group's Family Office and Private Wealth Management Forum? Don't miss Coherus Oncology's CEO Denny Lanfear's presentation tomorrow and meet with the Coherus Oncology team.
1
373
We are excited to participate in SITC’s Targets for Cancer IO webinar and discuss CCR8 as a therapeutic target in oncology and share our clinical experience with CHS-114, our highly selective cytolytic anti-CCR8 mAb. Register to attend: bit.ly/3VEkGjx

Society for Immunotherapy of Cancer
@sitcancer
24 Sep 2025
Tune in on Oct. 22 for our Development of Anti-CCR8 Ab - Mechanisms and Clinical Results Webinar! We will address the novel therapeutic target C-C chemokine receptor 8 (CCR8), its role in regulatory T cell (Treg) activity and immunosuppression. Register: sitcancer.org/edu/webinars/t…
1
3
1,546
We look forward to sharing new biomarker data from our Phase 1 study of CHS-114 at the 40th Annual SITC Meeting in November. Read more about our presentation and upcoming SITC webinar: bit.ly/3VJT1h5
6
398
Tune in tomorrow for our fireside chat at UBS’s Virtual Oncology Day. We will discuss the latest developments with our novel oncology pipeline targeting the immune-suppressive mechanisms in the TME. Listen to the webcast: bit.ly/4mCSzvR
1
271
We’re proud to have partnered with NORD and Rep Mike Kelly (PA) to introduce a resolution recognizing Sept 30th as Rare Cancer Day. Join us in supporting patients & families affected by a cancer diagnosis, including those with a rare form. Learn more: bit.ly/4gJMvR8
2
285
Coherus Oncology’s CEO, Denny Lanfear, and Chief Scientific and Development Officer, Theresa LaVallee, are participating in a fireside chat with Douglas Tsao at the H.C. Wainwright 27th Annual Global Investment Conference today. Listen to the webcast here: bit.ly/46sQtdc
1
319
Coherus Oncology’s CEO, Denny Lanfear, and Chief Scientific and Development Officer, Theresa LaVallee, are participating in a fireside chat with Colleen Kusy at the Baird 2025 Global Healthcare Conference today. Listen to the webcast here: bit.ly/3Ie3UV6
3
325
Coherus Oncology is attending the following Fall Investor Conferences. For webcast links of our presentations, please visit: bit.ly/4nhV8EB To schedule 1x1 meetings during the conferences, please reach out to your respective bank representative.
3
283
Join us for our Q2 2025 earnings call today, starting at 5:00 p.m. ET, to hear about our Q2 financial results and business highlights. Press release: bit.ly/4mBp0vl and listen to the webcast: bit.ly/4fgZxVu
5
405
Coherus Oncology will report Q2 2025 financial results on August 7, 2025. Starting at 5 pm EDT, the $CHRS executive team will host a conference call and webcast to discuss Q2 2025 financial results and recent business highlights. Webcast: bit.ly/4fgZxVu
1
6
784
Attending #ASCO25? Come by Booth #11081 this weekend to meet the Coherus team and learn more about our products and innovative immuno-oncology pipeline.
3
1,540
Starting today, we are now Coherus Oncology, Inc. Our new name better reflects our strategic transformation to focus exclusively on innovative cancer therapeutics. Read more here: bit.ly/3SsBGHO
2
534
Join us for our Q1 2025 earnings call today, starting at 5:00 p.m. ET, to hear about our Q1 financial results and business highlights. Read our press release: bit.ly/4dob708 and listen to the webcast: bit.ly/3EOEHyY $CHRS
3
1,069
Coherus will report Q1 2025 financial results on May 12, 2025. Starting at 5 pm EDT, $CHRS executive team will host a conference call and webcast to discuss Q1 2025 financial results and recent business highlights. Webcast: bit.ly/3EOEHyY
7
1,193
Breaking News: Coherus completes strategic transformation with successful divestiture of UDENYCA® franchise. Read our press release for more: bit.ly/3XWNZ2d
6
511
We look forward to presenting interim data from our Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and with toripalimab in patients with HNSCC at the 2025 AACR Annual Meeting. For details: bit.ly/41IWvnO
1
6
880
Join us for our Q4-FY 2024 earnings call today, starting at 5:00 pm ET, to hear about our Q4 financial results and recent business highlights. Press release: bit.ly/41DvYa7and Listen to the webcast: bit.ly/4hlVgQ9
1
659
Load more